Detalles de la búsqueda
1.
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.
N Engl J Med
; 385(24): 2230-2240, 2021 12 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34879449
2.
Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial data.
Pediatr Dermatol
; 39(2): 187-196, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35083774
3.
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.
J Am Acad Dermatol
; 83(5): 1282-1293, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32574587
4.
Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study.
Am J Clin Dermatol
; 2024 May 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38743155
5.
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis.
Paediatr Drugs
; 26(2): 163-173, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38267692
6.
Long-Term Safety of Dupilumab in Patients With Moderate-to-Severe Asthma: TRAVERSE Continuation Study.
J Allergy Clin Immunol Pract
; 12(4): 991-997.e6, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38163585
7.
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study.
Lancet Respir Med
; 12(1): 45-54, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37956679
8.
TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation.
Mod Pathol
; 26(2): 195-203, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22936064
9.
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.
Adv Ther
; 40(1): 367-380, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36318387
10.
Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials.
Am J Clin Dermatol
; 24(3): 469-483, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36808602
11.
Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study.
J Dermatolog Treat
; 33(3): 1608-1616, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33557637
12.
Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccines.
J Allergy Clin Immunol Glob
; 1(1): 9-15, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37780074
13.
Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies.
J Allergy Clin Immunol Pract
; 10(3): 732-741, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34954123
14.
Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis.
J Allergy Clin Immunol Pract
; 10(10): 2695-2709, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35636689
15.
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Am J Clin Dermatol
; 23(3): 393-408, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35503163
16.
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.
Lancet Respir Med
; 10(1): 11-25, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34597534
17.
Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial.
Am J Clin Dermatol
; 22(2): 243-255, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33655423
18.
Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial.
Paediatr Drugs
; 23(5): 515-527, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34462864
19.
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Am J Clin Dermatol
; 22(1): 101-115, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33481203
20.
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Am J Clin Dermatol
; 21(4): 567-577, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32557382